Telsar Pharma Inc.
Latest From Telsar Pharma Inc.
Astellas Shuts U.S./EU Phase III Diabetes Trial But Resumes Asia Development For Differentiated Markets
Astellas’ multi-track R&D approach leaves door open for a Western partner interested in a Phase III SGLT2 inhibitor, but the Japanese pharma’s main interest is finding ipragliflozin’s niche in Asia.
Astellas’ multi-track R&D approach leaves door open for a western partner interested in a Phase III SGLT2 inhibitor, but the Japanese pharma’s main interest is finding ipragliflozin’s niche in Asia.
In the second quarter of 2012, start-up companies raised a total of $556 million across all industries. Most of that financing – $439.8 million – went to the biopharma sector. Cancer was the most prevalent therapeutic area for alliances. There were just four start-up acquisitions – two each in the biopharma and medical device industries.
Follow-on public offerings continued to dominate, with 19 transactions making up almost half of Q2’s $2.7 billion financing volume. M&A dollars, up nearly four times that of Q1, totaled $34.7 billion, for 28 completed transactions, seven of which topped the billion dollar mark. In alliances, the Q2 potential deal value – also largely increased over the previous quarter’s – marked possibly the highest amount ever seen along with maybe the most expensive deal ever: Walgreen $6.6 billion agreement to purchase a minority equity share in Alliance Boots, bringing in over half of Q2’s value.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Telsar Pharma Inc.
- Senior Management
Donna L Tempel, PhD, Pres. & CEO
Robert E Desjardins, MD, CSO
- Contact Info
Telsar Pharma Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.